<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: adversely affected", fill: "#0cc"},
{source: "3: adversely affected", target: "6: Acceptance ", fill: "#bf00ff"},
{source: "6: Acceptance ", target: "6: dependent", fill: "#bf00ff"},
{source: "6: dependent", target: "6: community", fill: "#bf00ff"},
{source: "6: community", target: "6: distinctive characteristics", fill: "#bf00ff"},
{source: "6: distinctive characteristics", target: "6: costeffectiveness", fill: "#bf00ff"},
{source: "6: costeffectiveness", target: "6: products compared", fill: "#bf00ff"},
{source: "6: products compared", target: "6: competitive products", fill: "#bf00ff"},
{source: "6: competitive products", target: "6: on training physicians", fill: "#bf00ff"},
{source: "6: on training physicians", target: "6: application", fill: "#bf00ff"},
{source: "6: Acceptance ", target: "25: negatively affected", fill: "#704241"},
{source: "25: negatively affected", target: "25: future growth projections", fill: "#704241"},
{source: "25: future growth projections", target: "25: compete successfully against", fill: "#704241"},
{source: "25: compete successfully against", target: "25: competitors", fill: "#704241"},
{source: "25: negatively affected", target: "31: health hazard", fill: "#e30022"},
{source: "31: health hazard", target: "31: meet product performance criteria", fill: "#e30022"},
{source: "31: meet product performance criteria", target: "31: specifications", fill: "#e30022"},
{source: "31: specifications", target: "31: could voluntarily recall", fill: "#e30022"},
{source: "31: health hazard", target: "36: manufacturing difficulties", fill: "#66023c"},
{source: "36: manufacturing difficulties", target: "36: may unilaterally decide", fill: "#66023c"},
{source: "36: may unilaterally decide", target: "36: stop supplying us", fill: "#66023c"},
{source: "36: stop supplying us", target: "36: product liability concerns", fill: "#66023c"},
{source: "36: manufacturing difficulties", target: "43: Regulatory ", fill: "#26619c"},
{source: "43: Regulatory ", target: "43: authorities", fill: "#26619c"},
{source: "43: authorities", target: "43: world dictate different levels", fill: "#26619c"},
{source: "43: world dictate different levels", target: "43: manufacturing", fill: "#26619c"},
{source: "43: manufacturing", target: "43: andor clinical data", fill: "#26619c"},
{source: "43: Regulatory ", target: "61: may lose market", fill: "#f3c"},
{source: "61: may lose market", target: "61: competitors", fill: "#f3c"},
{source: "61: competitors", target: "61: intellectual property", fill: "#f3c"},
{source: "61: intellectual property", target: "61: adequately protect", fill: "#f3c"},
{source: "61: may lose market", target: "80: could incur significant costs", fill: "#2f847c"},
{source: "80: could incur significant costs", target: "80: significant", fill: "#2f847c"},
{source: "80: significant", target: "80: negative impacts", fill: "#2f847c"},
{source: "80: negative impacts", target: "80: product liability", fill: "#2f847c"},
{source: "80: product liability", target: "80: against us", fill: "#2f847c"},
{source: "80: could incur significant costs", target: "82: liability", fill: "#6a5acd"},
{source: "82: liability", target: "106: inability", fill: "#900"},
{source: "106: inability", target: "106: requirements", fill: "#900"},
{source: "106: requirements", target: "106: adversely", fill: "#900"},
{source: "106: inability", target: "START_HERE", fill: "#900"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Assets_under_management">Assets under management</a></td>
      <td>In finance, assets under management (AUM), sometimes called funds under management, measures the total market value of all the financial assets which an individual or financial institution—such as a mutual fund, venture capital firm, or depository institution—or a decentralized network protocol controls, typically on behalf of a client.  These funds may be managed for clients/users or for themselves in the case of a financial institution which has mutual funds or holds its own venture capital.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Ivor_Montagu">Ivor Montagu</a></td>
      <td>Ivor Goldsmid Samuel Montagu (23 April 1904, in Kensington, London – 5 November 1984, in Watford) was an English filmmaker, screenwriter, producer, film critic, writer, table tennis player, and Communist activist in the 1930s. He helped to develop a lively intellectual film culture in Britain during the interwar years, and was also the founder of the International Table Tennis Federation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Day_the_Music_Died">The Day the Music Died</a></td>
      <td>On February 3, 1959, American rock and roll musicians Buddy Holly, Ritchie Valens, and "The Big Bopper" J. P. Richardson were killed in a plane crash near Clear Lake, Iowa, together with pilot Roger Peterson. The event later became known as "The Day the Music Died" after singer-songwriter Don McLean referred to it as such in his 1971 song "American Pie".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Decree_nisi">Decree nisi</a></td>
      <td>A decree nisi or rule nisi (from Latin  nisi 'unless') is a court order that will come into force at a future date unless a particular condition is met. Unless the condition is met, the ruling becomes a decree absolute (rule absolute), and is binding.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/North_American_Free_Trade_Agreement">North American Free Trade Agreement</a></td>
      <td>The North American Free Trade Agreement (NAFTA ; Spanish: Tratado de Libre Comercio de América del Norte, TLCAN; French: Accord de libre-échange nord-américain, ALÉNA) was an agreement signed by Canada, Mexico, and the United States that created a trilateral trade bloc in North America. The agreement came into force on January 1, 1994, and superseded the 1988 Canada–United States Free Trade Agreement between the United States and Canada.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_analysis">Competitor analysis</a></td>
      <td>Competitive analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors. This analysis provides both an offensive and defensive strategic context to identify opportunities and threats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_backlinking">Competitor backlinking</a></td>
      <td>Competitor backlinking is a search engine optimization strategy that involves analyzing the backlinks of competing websites within a vertical search. The outcome of this activity is designed to increase organic search engine rankings and to gain an understanding of the link building strategies used by business competitors.By analyzing the backlinks to competitor websites, it is possible to gain a benchmark on the number of links and the quality of links that is required for high search engine rankings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitors_for_the_Crown_of_Scotland">Competitors for the Crown of Scotland</a></td>
      <td>When the crown of Scotland became vacant in September 1290 on the death of the seven-year-old child Queen Margaret, 13 claimants to the throne came forward. Those with the most credible claims were John Balliol, Robert Bruce, John Hastings and Floris V, Count of Holland.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sport_of_athletics">Sport of athletics</a></td>
      <td>Athletics is a group of sporting events that involves competitive running, jumping, throwing, and walking. The most common types of athletics competitions are track and field, road running, cross country running, and racewalking.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_female_fitness_and_figure_competitors">List of female fitness and figure competitors</a></td>
      <td>This is a list of female fitness and figure competitors.\n\n\n== A ==\nJelena Abbou\n\n\n== B ==\nLauren Beckham\nAlexandra Béres\nSharon Bruneau\n\n\n== C ==\nNatalie Montgomery-Carroll\nJen Cassetty\nKim Chizevsky\nSusie Curry\n\n\n== D ==\nDebbie Dobbins\nNicole Duncan\n\n\n== E ==\nJamie Eason\nAlexis Ellis\n\n\n== F ==\nAmy Fadhli\nJaime Franklin\n\n\n== G ==\nAdela García \nConnie Garner\nElaine Goodlad\nTracey Greenwood\nOksana Grishina\n\n\n== H ==\nMallory Haldeman\nVanda Hădărean\nJen Hendershott\nSoleivi Hernandez\nApril Hunter\n\n\n== I ==\n\n\n== J ==\nTsianina Joelson\n\n\n== K ==\nAdria Montgomery-Klein\nAshley Kaltwasser\n\n\n== L ==\nLauren Lillo\nMary Elizabeth Lado\nTammie Leady\nJennifer Nicole Lee\nAmber Littlejohn\nJulie Lohre\nJenny Lynn\n\n\n== M ==\nTimea Majorová\nLinda Maxwell\nDavana Medina\nJodi Leigh Miller\nChisato Mishima\n\n\n== N ==\nKim Nielsen\n\n\n== O ==\n\n\n== P ==\nVicky Pratt\nElena Panova\nChristine Pomponio-Pate\nCathy Priest\n\n\n== Q ==\n\n\n== R ==\nMaite Richert\nCharlene Rink\nKelly Ryan\n\n\n== S ==\nErin Stern\nCarol Semple-Marzetta\nKrisztina Sereny\nTrish Stratus (Patricia Anne Stratigias)\n\n\n== T ==\nKristi Tauti\nJennifer Thomas\n\n\n== U ==\n\n\n== V ==\nLisa Marie Varon\n\n\n== W ==\nLatisha Wilder\nTorrie Wilson\nLyen Wong\nJenny Worth\nNicole Wilkins\n\n\n== Y ==\n\n\n== Z ==\nMarietta Žigalová\nMalika Zitouni\n\n\n== See also ==\nList of female bodybuilders\n\n\n== References ==\nThere has been a rise in the number of women wanting to compete as fitness models.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Round-robin_tournament">Round-robin tournament</a></td>
      <td>A round-robin tournament (or all-play-all tournament) is a competition in which each contestant meets every other participant, usually in turn. A round-robin contrasts with an elimination tournament, in which participants are eliminated after a certain number of losses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_requirements_specification">Software requirements specification</a></td>
      <td>A software requirements specification (SRS) is a description of a software system to be  developed. It is modeled after business requirements specification (CONOPS).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Legal_liability">Legal liability</a></td>
      <td>In law, liable means  "responsible or answerable in law; legally obligated". Legal liability concerns both civil law and criminal law and can arise from various areas of law, such as contracts, torts, taxes, or fines given by government agencies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Liability_(financial_accounting)">Liability (financial accounting)</a></td>
      <td>In financial accounting, a liability is defined as the future sacrifices of economic benefits that the entity is\nobliged to make to other entities as a result of past transactions or other past events, the settlement of which may result in the transfer or use of assets, provision of services or other yielding of economic benefits in the future.\n\n\n== Characteristics ==\nA liability is defined by the following characteristics:\n\nAny type of borrowing from persons or banks for improving a business or personal income that is payable during short or long time;\nA duty or responsibility to others that entails settlement by future transfer or use of assets, provision of services, or other transaction yielding an economic benefit, at a specified or determinable date, on occurrence of a specified event, or on demand;\nA duty or responsibility that obligates the entity to another, leaving it little or no discretion to avoid settlement; and,\nA transaction or event obligating the entity that has already occurredLiabilities in financial accounting need not be legally enforceable; but can be based on equitable obligations or constructive obligations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_Consent">Manufacturing Consent</a></td>
      <td>Manufacturing Consent: The Political Economy of the Mass Media is a 1988 book by Edward S. Herman and Noam Chomsky. It argues that the mass communication media of the U.S. "are effective and powerful ideological institutions that carry out a system-supportive propaganda function, by reliance on market forces, internalized assumptions, and self-censorship, and without overt coercion", by means of the propaganda model of communication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Textile_manufacturing">Textile manufacturing</a></td>
      <td>Textile manufacturing is a major industry. It is largely based on the conversion of fibre into yarn, then yarn into fabric.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Murata_Manufacturing">Murata Manufacturing</a></td>
      <td>Murata Manufacturing Co., Ltd. (株式会社村田製作所, Kabushiki-gaisha Murata Seisakusho) is a Japanese manufacturer of electronic components, based in Nagaokakyo, Kyoto.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/World_Intellectual_Property_Organization">World Intellectual Property Organization</a></td>
      <td>The World Intellectual Property Organization (WIPO; French: Organisation mondiale de la propriété intellectuelle (OMPI)) is one of the 15 specialized agencies of the United Nations (UN). Pursuant to the 1967 Convention Establishing the World Intellectual Property Organization, WIPO was created to promote and protect intellectual property (IP) across the world by cooperating with countries as well as international organizations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property_infringement">Intellectual property infringement</a></td>
      <td>An intellectual property (IP) infringement is the infringement or violation of an intellectual property right. There are several types of intellectual property rights, such as copyrights, patents, trademarks, industrial designs, and trade secrets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/TRIPS_Agreement">TRIPS Agreement</a></td>
      <td>The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is an international legal agreement between all the member nations of the World Trade Organization (WTO). It establishes minimum standards for the regulation by national governments of different forms of intellectual property (IP) as applied to nationals of other WTO member nations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/World_Intellectual_Property_Indicators">World Intellectual Property Indicators</a></td>
      <td>World Intellectual Property Indicators (WIPI) is an annual statistical report published by the World Intellectual Property Organization (WIPO). The publication provides an overview of the activity in the areas of patents, utility models, trademarks, industrial designs, microorganisms, plant variety protection, geographical indications and the creative economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property_in_India">Intellectual property in India</a></td>
      <td>Intellectual property in India refers to the patents, copyrights and other intangible assets in India.\n\n\n== Government Policy ==\nIndian government approved its first Intellectual Property Rights Policy in May 2016.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Liability_insurance">Liability insurance</a></td>
      <td>Liability insurance (also called third-party insurance) is a part of the general insurance system of risk financing to protect the purchaser (the "insured") from the risks of liabilities imposed by lawsuits and similar claims and protects the insured if the purchaser is sued for claims that come within the coverage of the insurance policy.\nOriginally, individual companies that faced a common peril formed a group and created a self-help fund out of which to pay compensation should any member incur loss (in other words, a mutual insurance arrangement).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Limited_liability">Limited liability</a></td>
      <td>Limited liability is a legal status where a person's financial liability is limited to a fixed sum, most commonly the value of a person's investment in a corporation, company or partnership. If a company that provides limited liability to its investors is sued, then the claimants are generally entitled to collect only against the assets of the company, not the assets of its shareholders or other investors.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/No_liability">No liability</a></td>
      <td>A no-liability company in Australia (suffix NL) is a company which, under the Corporations Act 2001 (Cth), must have as its stated objects that it is solely a mining company and that it is not entitled to calls on the unpaid issue price of shares. It is a company which is restricted to mining activities and is the only sort of corporation which is entitled to this form of liability, given the sometimes financially risky business of mining.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Limited_liability_partnership">Limited liability partnership</a></td>
      <td>A limited liability partnership (LLP) is a partnership in which some or all partners (depending on the jurisdiction) have limited liabilities. It therefore can exhibit elements of partnerships and corporations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirement">Requirement</a></td>
      <td>In product development and process optimization, a requirement is a singular documented physical or functional need that a particular design, product or process aims to satisfy. It is commonly used in a formal sense in engineering design, including for example in systems engineering, software engineering, or enterprise engineering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_engineering">Requirements engineering</a></td>
      <td>Requirements engineering (RE) is the process of defining, documenting, and maintaining requirements in the engineering design process. It is a common role in systems engineering and software engineering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Visa_requirements_for_United_States_citizens">Visa requirements for United States citizens</a></td>
      <td>As of 25 February 2022, Holders of a United States passport could travel to 186 countries and territories without a travel visa, or with a visa on arrival. The United States passport currently ranks 6th in terms of travel freedom (tied with the passports of Czech Republic, Greece, Malta, Norway, and the UK) according to the Henley Passport Index.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_elicitation">Requirements elicitation</a></td>
      <td>In requirements engineering, requirements elicitation is the practice of researching and discovering the requirements of a system from users, customers, and other stakeholders. The practice is also sometimes referred to as "requirement gathering".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/System_requirements_specification">System requirements specification</a></td>
      <td>A System Requirements Specification (SyRS) (abbreviated SysRS when need to be distinct from a software requirements specification (SRS)) is a structured collection of information that embodies the requirements of a system.A business analyst (BA), sometimes titled system analyst, is responsible for analyzing the business needs of their clients and stakeholders to help identify business problems and propose solutions. Within the systems development life cycle domain, the BA typically performs a liaison function between the business side of an enterprise and the information technology department or external service providers.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>AMERICAN MEDICAL SYSTEMS HOLDINGS INC      Item 1A Risk Factors     The <font color="blue">following risk factors should</font> be considered <font color="blue">carefully</font> in <font color="blue">connection with</font>     any <font color="blue">evaluation</font> of our business, <font color="blue">financial condition</font>, results of <font color="blue">operations</font>,     prospects and an <font color="blue">investment</font> in our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Additionally, the following     risk factors could cause our actual results to <font color="blue">materially</font> differ from those     reflected in any forward-looking statements</td>
    </tr>
    <tr>
      <td>Our  sales may be <font color="blue"><font color="blue">adversely</font> affected</font> if physicians do not recommend or     endorse our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely upon physicians</font> to recommend, endorse and accept our products</td>
    </tr>
    <tr>
      <td><font color="blue">Many     </font>of the products we acquired or are developing are <font color="blue">based on new treatment</font>     methods</td>
    </tr>
    <tr>
      <td><font color="blue">Acceptance </font>of our products is <font color="blue">dependent</font> on educating the medical     <font color="blue">community</font>  as  to the <font color="blue">distinctive characteristics</font>, perceived benefits,     clinical  efficacy, and cost-effectiveness of our <font color="blue">products compared</font> to     <font color="blue"><font color="blue">competitive</font> products</font>, and <font color="blue">on training physicians</font> in the proper <font color="blue">application</font>     of our products</td>
    </tr>
    <tr>
      <td>We believe our <font color="blue">products address major market opportunities</font>,     but if we are <font color="blue">unsuccessful</font> in <font color="blue">marketing them</font>, our sales and <font color="blue">earnings could</font>     be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">growth will</font> be slowed if <font color="blue">new products</font> are delayed or are not accepted</td>
    </tr>
    <tr>
      <td>As part of our <font color="blue">growth strategy</font>, we intend to introduce a number of new     products and <font color="blue">product improvements</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue"><font color="blue">introduction</font>s depend upon</font> a     variety of factors, including <font color="blue">timely receipt</font> of <font color="blue"><font color="blue">appropriate</font> <font color="blue">regulatory</font></font>     approvals</td>
    </tr>
    <tr>
      <td>If  we  do  not  introduce  these <font color="blue">new products</font> and product     <font color="blue">improvements on schedule</font>, for any reason, or if they are not <font color="blue">well accepted</font>     by the market, our business may be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">sales <font color="blue">could decline</font></font> if our procedures are not <font color="blue">accepted by patients</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">predominantly sell implants</font> and therapies for <font color="blue">surgical procedures</font> or     therapies</td>
    </tr>
    <tr>
      <td>Patient <font color="blue">acceptance</font> of our products and therapies depends on a     number of factors, including the failure of non-invasive therapies, the     degree of <font color="blue">invasiveness involved</font> in the <font color="blue">procedures using</font> our products, the     rate and severity of <font color="blue">complications</font>, and other adverse side <font color="blue">effects from</font> the     <font color="blue">procedures using</font> our products</td>
    </tr>
    <tr>
      <td>Patients are more likely to first consider     non-invasive alternatives to treat their <font color="blue">urological disorders</font></td>
    </tr>
    <tr>
      <td><font color="blue">Broader     </font>patient <font color="blue">acceptance</font> of <font color="blue">alternative therapies</font> or the <font color="blue">introduction</font> of new oral     <font color="blue">medications</font> or other less-invasive therapies could <font color="blue">adversely</font> affect our     business</td>
    </tr>
    <tr>
      <td>Changes in third party <font color="blue">reimbursement</font> for our products and therapies may     influence our customers’ purchasing activity</td>
    </tr>
    <tr>
      <td>Our physician and <font color="blue">hospital customers depend on third party government</font> and     non-government entities around the world to <font color="blue">reimburse them</font> for services     provided  to patients</td>
    </tr>
    <tr>
      <td>The level of such third party <font color="blue">reimbursement</font> has     <font color="blue">fluctuated from</font> time to time in the past, may fluctuate in the future, and     is subject to review or <font color="blue">withdrawal at</font> any time</td>
    </tr>
    <tr>
      <td>The level of <font color="blue">reimbursement</font>     <font color="blue">may influence whether customers purchase</font> our products</td>
    </tr>
    <tr>
      <td>Further, as we expand     our offerings from implants surgically delivered to patients in hospital     settings to minimally-invasive therapies delivered to patients in physician     offices, we <font color="blue">must address</font> the information needs of varied <font color="blue">reimbursement</font>     systems and processes</td>
    </tr>
    <tr>
      <td>While our <font color="blue">sales history</font> of devices in the US does     not reflect an <font color="blue">obvious correlation between sales levels</font> and changes in CMS     <font color="blue">reimbursement</font> rates, office-based                                         8       _________________________________________________________________    [48]Table of <font color="blue">Contents       </font>business may be more directly impacted by <font color="blue">reimbursement</font> rate fluctuations     than our hospital-based business has <font color="blue">been historically</font></td>
    </tr>
    <tr>
      <td>Any unfavorable     change in <font color="blue">reimbursement</font> could have a <font color="blue">negative <font color="blue">impact on</font></font> our business</td>
    </tr>
    <tr>
      <td>Our revenues and operating results may be <font color="blue"><font color="blue">negatively</font> affected</font> and we may not     achieve <font color="blue">future growth projections</font> if we fail to <font color="blue">compete <font color="blue">successfully</font> against</font>     our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>Many  of  our <font color="blue">competitors</font> have greater resources, more widely accepted     products,  <font color="blue">less invasive</font> therapies, greater technical <font color="blue">capabilities</font> and     stronger name <font color="blue">recognition</font> in individual product <font color="blue">categories</font> than we do</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">competitors</font>  will  continue  to improve their products and develop new     <font color="blue">competing products</font>, including <font color="blue">less invasive</font> or <font color="blue">noninvasive products</font> or     <font color="blue">pharmaceuticals</font></td>
    </tr>
    <tr>
      <td>We  may  be  unable  to <font color="blue">compete effectively with</font> our     <font color="blue">competitors</font> if we cannot keep <font color="blue">up with existing</font> or <font color="blue">new alternative products</font>,     techniques, therapies and <font color="blue">technology</font> in the markets we serve</td>
    </tr>
    <tr>
      <td>These new     <font color="blue">technologies</font> and products may beat our products to the market, be more     <font color="blue">effective than</font> our products or render our <font color="blue">products obsolete by substantially</font>     reducing the prevalence of the <font color="blue">conditions</font> our products and <font color="blue">therapies treat</font></td>
    </tr>
    <tr>
      <td>We may experience an <font color="blue">interruption</font> in sales of a product and <font color="blue">incur costs</font> if     that product is recalled</td>
    </tr>
    <tr>
      <td>In the event that any of our products present a <font color="blue">health hazard</font> to the patient     or physician or fail to <font color="blue">meet product performance criteria</font> or <font color="blue">specifications</font>,     we  <font color="blue">could voluntarily recall</font> the products</td>
    </tr>
    <tr>
      <td>The FDA or an <font color="blue">international</font>     <font color="blue">regulatory</font> body <font color="blue">could also</font> require us to recall the products</td>
    </tr>
    <tr>
      <td>There is a     <font color="blue">possibility</font>  that we <font color="blue">may recall products</font> in the future and that future     <font color="blue">recalls could</font> result in <font color="blue"><font color="blue">significant</font> costs</font> to us and in <font color="blue"><font color="blue">significant</font> negative</font>     <font color="blue">publicity which could harm</font> our ability to market our products in the future</td>
    </tr>
    <tr>
      <td>We  may  not  be able to <font color="blue">supply products</font> that <font color="blue">incorporate materials</font> or     <font color="blue"><font color="blue">components</font> which</font> are single- or sole-sourced</td>
    </tr>
    <tr>
      <td>Many of our products utilize <font color="blue">raw materials</font> or <font color="blue">components</font> that are either     single-or  sole-sourced</td>
    </tr>
    <tr>
      <td>These  sources  of  supply  could  encounter     <font color="blue"><font color="blue">manufacturing</font> <font color="blue">difficult</font>ies</font> or <font color="blue">may unilaterally decide</font> to <font color="blue">stop supplying us</font>     because of <font color="blue"><font color="blue">product <font color="blue">liability</font></font> concerns</font> or other factors</td>
    </tr>
    <tr>
      <td>We <font color="blue">currently rely on</font>     single  source  suppliers for the silicone and <font color="blue">fabric used</font> in our male     prostheses and for the <font color="blue">porcine dermis</font> and mesh used in many of our female     products</td>
    </tr>
    <tr>
      <td>Furthermore, we <font color="blue">use <font color="blue">single source</font>s</font> for the TherMatrx consoles and     <font color="blue">disposables</font></td>
    </tr>
    <tr>
      <td>A key component of the InhibiZone antibiotic <font color="blue">technology</font> is also     <font color="blue">procured from</font> a <font color="blue">single source</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">no written <font color="blue">agreements</font> with</font> our key     suppliers  requiring  them  to  supply  us with these <font color="blue">raw materials</font> or     <font color="blue">components</font>, and there is no assurance that we would be able to timely or     cost-effectively replace any of these <font color="blue">sources upon</font> any <font color="blue">disruption</font></td>
    </tr>
    <tr>
      <td>The loss     of  any of these <font color="blue">suppliers could</font> have a material adverse effect on our     financial results in the near term, as we would be required to qualify     <font color="blue">alternate designs</font> or sources</td>
    </tr>
    <tr>
      <td><font color="blue">Inadequate </font><font color="blue">data submissions</font> or <font color="blue">clinical study</font> results which do not support a     <font color="blue"><font color="blue">product approval</font> may delay</font> or preclude a product’s <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory  </font><font color="blue">authorities</font>  around  the <font color="blue">world dictate different levels</font> of     <font color="blue">manufacturing</font>  and design information and/or clinical data for various     products and therapies in order to ensure their safety and efficacy</td>
    </tr>
    <tr>
      <td>In the     event the data submitted is deemed inadequate or the <font color="blue">clinical study</font> results     do  not  support  approval,  a  product  may  either  not  be  fit for     <font color="blue">commercialization</font>  or may require a redesign to satisfy the <font color="blue">regulatory</font>     <font color="blue">authorities</font> and/or <font color="blue">clinical study</font> outcomes</td>
    </tr>
    <tr>
      <td>In addition, though a product’s     clinical results may meet the <font color="blue">regulatory</font> <font color="blue">requirements</font> for <font color="blue">product approval</font>     and <font color="blue">commercialization</font>, market <font color="blue">acceptance</font> and adoption of the <font color="blue">product may</font> not     meet our <font color="blue">expectations</font></td>
    </tr>
    <tr>
      <td>Our  sale  of <font color="blue">products could</font> be reduced if we are unable to obtain the     <font color="blue">regulatory</font> approvals <font color="blue">necessary</font> to market our products in the <font color="blue"><font color="blue"><font color="blue">United States</font> </font>    </font>and foreign <font color="blue">jurisdictions</font></td>
    </tr>
    <tr>
      <td>If we fail to receive <font color="blue">regulatory</font> approval for <font color="blue">future products</font>, we will be     unable to market and sell these products</td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States</font>, we must     obtain <font color="blue">approval from</font> the FDA before we can <font color="blue">begin commercializing most</font> of our     products</td>
    </tr>
    <tr>
      <td>The FDA approval process is <font color="blue">typically lengthy</font> and expensive, and     approval is <font color="blue">never certain</font></td>
    </tr>
    <tr>
      <td>Products <font color="blue">distributed outside</font> of the <font color="blue"><font color="blue"><font color="blue">United States</font> </font>    </font>are also subject to foreign government <font color="blue">regulations</font> which vary from country     to country</td>
    </tr>
    <tr>
      <td>The time required to obtain <font color="blue">approval from</font> a foreign country may     be longer or <font color="blue">shorter than</font> that required for FDA clearance</td>
    </tr>
    <tr>
      <td>Our failure to     <font color="blue">comply with</font> <font color="blue">regulatory</font> approvals could result in government <font color="blue">authorities</font>:       •   <font color="blue">imposing fines</font> and <font color="blue">penalties on us</font>;         •   preventing us from <font color="blue">manufacturing</font> our products;                                         9       _________________________________________________________________    [49]Table of <font color="blue">Contents       </font>  •   <font color="blue">bringing civil</font> or <font color="blue">criminal charges <font color="blue">against us</font></font>;         •   delaying the <font color="blue">introduction</font> of our <font color="blue">new products</font> into the market;         •   recalling or seizing our products;         •   disrupting the <font color="blue">manufacture</font> or <font color="blue">distribution</font> of our products; or         •   withdrawing or <font color="blue">denying approvals</font> for our products</td>
    </tr>
    <tr>
      <td>In the event we fail to <font color="blue">comply with</font> <font color="blue">manufacturing</font> <font color="blue">regulations</font>, we could be     prevented from selling our products</td>
    </tr>
    <tr>
      <td>In order to commercially <font color="blue">manufacture</font> our products, we <font color="blue">must <font color="blue">comply with</font></font> the     FDA’s  <font color="blue">manufacturing</font> <font color="blue">regulations</font> which govern design controls, quality     systems and <font color="blue">documentation policies</font> and procedures</td>
    </tr>
    <tr>
      <td>The FDA and foreign     <font color="blue">authorities</font> <font color="blue">periodically</font> inspect our <font color="blue">manufacturing</font> <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>Our failure     to <font color="blue">comply with</font> these <font color="blue">manufacturing</font> <font color="blue">regulations</font> may <font color="blue">prevent us</font> or <font color="blue">delay us</font>     <font color="blue">from marketing</font> or <font color="blue">distributing</font> our products and this would have a negative     <font color="blue">impact on</font> our business</td>
    </tr>
    <tr>
      <td>Our business may suffer if our <font color="blue">new products</font> are not cleared to market in the     <font color="blue"><font color="blue">United States</font> </font>or any other market</td>
    </tr>
    <tr>
      <td>We sell some of our <font color="blue">products only</font> in <font color="blue">international</font> markets because they have     not <font color="blue">been cleared</font> for marketing in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We may be unable to     sell <font color="blue">future products</font> in Europe, the <font color="blue"><font color="blue">United States</font> </font>or any other market for a     number of reasons</td>
    </tr>
    <tr>
      <td>These reasons include, <font color="blue">among others</font>, that the potential     <font color="blue">products could</font> be:       •   <font color="blue">ineffective</font> or cause harmful side <font color="blue">effects during preclinical testing</font>     or <font color="blue">clinical trials</font>;         •   <font color="blue">difficult</font> to <font color="blue">manufacture</font> on a large scale; or         •   uneconomical for the healthcare <font color="blue">reimbursement</font> system</td>
    </tr>
    <tr>
      <td>We <font color="blue">may lose market</font> share to our <font color="blue">competitors</font> and be unable to operate our     business profitably in the event our patents and other <font color="blue">intellectual property</font>     rights do not <font color="blue">adequately protect</font> our products and therapies</td>
    </tr>
    <tr>
      <td>We rely on patents, <font color="blue">trade secrets</font>, copyrights, know-how, trademarks, license     <font color="blue">agreements</font> and <font color="blue">contractual provisions</font> to establish our <font color="blue">intellectual property</font>     rights and protect our products</td>
    </tr>
    <tr>
      <td>These legal means, however, afford only     limited protection and may not <font color="blue">adequately protect</font> our rights</td>
    </tr>
    <tr>
      <td>In addition,     we cannot be assured that pending patent <font color="blue">application</font>s will issue</td>
    </tr>
    <tr>
      <td>The US     Patent and Trademark Office (PTO) may deny or <font color="blue">significant</font>ly narrow claims     made under patent <font color="blue">application</font>s and the <font color="blue">issued patents</font>, if any, may not     provide  us  with  <font color="blue">significant</font>  commercial  protection</td>
    </tr>
    <tr>
      <td>We <font color="blue">could incur</font>     substantial costs in <font color="blue">proceedings</font> before the PTO These <font color="blue">proceedings</font> could     result  in  <font color="blue">adverse decisions as</font> to the priority of our <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>In     addition, the laws of some of the countries in which our products are or may     be sold may not protect our products and <font color="blue">intellectual property</font> to the same     extent as US laws, or at all</td>
    </tr>
    <tr>
      <td>We may be unable to protect our rights in     <font color="blue">trade secrets</font> and unpatented proprietary <font color="blue">technology</font> in these countries</td>
    </tr>
    <tr>
      <td>We seek to protect our <font color="blue">trade secrets</font> and unpatented proprietary <font color="blue">technology</font>,     in part, with confidentiality <font color="blue">agreements</font> with our employees and <font color="blue">consultants</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you, however, that:       •   these <font color="blue">agreements</font> will not be breached;         •   we will have <font color="blue">adequate remedies</font> for any breach; or         •   <font color="blue">trade secrets</font> will not <font color="blue">otherwise become known</font> to or in<font color="blue">dependent</font>ly     developed by our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>In  the  event of a claim that we infringe upon another’s intellectual     <font color="blue">property rights</font>, we <font color="blue">could incur</font> <font color="blue"><font color="blue">significant</font> costs</font> and/or be required to stop     the sale of the related product</td>
    </tr>
    <tr>
      <td>The medical device industry is <font color="blue">highly litigious with respect</font> to patents and     other <font color="blue">intellectual property</font> rights</td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font>in the medical device industry     have used <font color="blue">intellectual property</font> <font color="blue">litigation</font> to seek to gain a <font color="blue">competitive</font>     advantage</td>
    </tr>
    <tr>
      <td>In the future, we may become a party to lawsuits involving     patents or other <font color="blue">intellectual property</font></td>
    </tr>
    <tr>
      <td>A legal proceeding, regardless of     the outcome, would draw upon our <font color="blue">financial resources</font> and divert the time and     efforts of our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>If we lose one of these <font color="blue">proceedings</font>, a court, or     a  similar <font color="blue">foreign governing</font> body, could require us to pay <font color="blue">significant</font>     damages to <font color="blue">third parties</font>, require us to seek licenses from <font color="blue">third parties</font> and     <font color="blue">pay ongoing royalties</font>, require us to redesign our products, or <font color="blue">prevent us</font>     from <font color="blue">manufacturing</font>, using or selling our products</td>
    </tr>
    <tr>
      <td>In addition to being     costly, protracted <font color="blue">litigation</font> to defend or enforce                                         10       _________________________________________________________________    [50]Table of <font color="blue">Contents       </font>our <font color="blue">intellectual property</font> rights could result in our customers or potential     customers  <font color="blue">deferring</font> or limiting their purchase or use of the affected     <font color="blue">products until</font> the <font color="blue">litigation</font> is resolved</td>
    </tr>
    <tr>
      <td>We may be involved in future     <font color="blue">proceedings</font>  before  the  US  PTO  with regard to <font color="blue">three requests</font> for     <font color="blue">interference</font>  claims filed by Conceptus, Inc</td>
    </tr>
    <tr>
      <td><font color="blue">against two</font> Ovion patent     <font color="blue">application</font>s and one Ovion patent</td>
    </tr>
    <tr>
      <td>We <font color="blue">could incur</font> <font color="blue"><font color="blue">significant</font> costs</font> or other <font color="blue">negative impacts</font> if <font color="blue">significant</font>     <font color="blue">product <font color="blue">liability</font></font> claims are made <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> and sale of <font color="blue">medical devices exposes us</font> to <font color="blue">significant</font> risk     of <font color="blue">product <font color="blue">liability</font></font> claims</td>
    </tr>
    <tr>
      <td>In the past, we have had a number of product     <font color="blue">liability</font> claims relating to our products</td>
    </tr>
    <tr>
      <td>In the future, we may be subject     to <font color="blue">additional</font> <font color="blue">product <font color="blue">liability</font></font> claims, some of which may have a negative     <font color="blue">impact on</font> our business</td>
    </tr>
    <tr>
      <td>As our product and therapy portfolio broadens into     the treatment of <font color="blue">additional</font> medical indications, our <font color="blue">historical product</font>     <font color="blue">liability</font> experience may not be a <font color="blue">reflection</font> of our <font color="blue">longer term future</font>     exposure</td>
    </tr>
    <tr>
      <td>If a <font color="blue">product <font color="blue">liability</font></font> claim or series of claims is brought     against  us  for uninsured <font color="blue">liabilities</font> or for amounts in excess of our     <font color="blue">insurance coverage</font>, our business <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>If physician malpractice insurance costs increase, at some point physicians     may alter their <font color="blue">practice patterns</font> and <font color="blue">cease using</font> our products</td>
    </tr>
    <tr>
      <td>Unless the patients who would have been treated by     these physicians are referred to other physicians, sales of our products     <font color="blue">could decline</font></td>
    </tr>
    <tr>
      <td>If  we  are <font color="blue">unsuccessful</font> in <font color="blue">integrating <font color="blue">acquisition</font>s</font>, our business and     <font color="blue">financial condition</font> could be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>We have acquired <font color="blue">businesses</font> in the past and we may acquire other <font color="blue">businesses</font>     in the future</td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">successfully</font> retain critical employees of an     acquired  company, failure to gain FDA approval for the products of an     acquired company, or the <font color="blue">inability</font> to establish and maintain <font color="blue">appropriate</font>     communications, performance <font color="blue">expectations</font>, <font color="blue">regulatory</font> compliance procedures,     <font color="blue">accounting controls</font>, and reporting <font color="blue">procedures could</font> have a material adverse     affect  on our business</td>
    </tr>
    <tr>
      <td>Once an <font color="blue">acquisition</font> is completed, we may also     experience:       •   <font color="blue">difficult</font>ies in <font color="blue">assimilating</font> any acquired companies and products into     our existing business;         •   delays in realizing the benefits of the acquired company or products;         •   diversion of our <font color="blue">management</font>’s time and <font color="blue">attention from</font> other business     concerns;         •   lack of or limited direct experience in <font color="blue">new markets</font> we may enter; or         •   <font color="blue">difficult</font>ies in retaining <font color="blue">key employees</font> of the acquired business     <font color="blue">necessary</font> to manage these <font color="blue">acquisition</font>s</td>
    </tr>
    <tr>
      <td>In addition, an <font color="blue">acquisition</font> could <font color="blue">materially</font> impair our operating results by     causing us to incur debt or requiring us to amortize <font color="blue">acquisition</font> expenses     and acquired assets</td>
    </tr>
    <tr>
      <td>Loss of our <font color="blue">manufacturing</font> <font color="blue">facility</font> would <font color="blue">adversely</font> affect our financial     position</td>
    </tr>
    <tr>
      <td>We  are  currently  operating with one <font color="blue">manufacturing</font> shift at a single     <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>Although we believe we have <font color="blue">adequate physical capacity</font> to serve     our business <font color="blue">operations</font> for the <font color="blue">foreseeable future</font>, we do not have a back up     <font color="blue">facility</font>, and the loss of our <font color="blue">Minnetonka </font><font color="blue">facility</font> would have a material     adverse effect on our sales, earnings, and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td><font color="blue">Changes  </font>in  <font color="blue">international</font>  stability  or foreign exchange rates could     <font color="blue">negatively</font> impact our sales</td>
    </tr>
    <tr>
      <td>During the fiscal 2005, <font color="blue">approximately</font> 21dtta8 percent of our sales were to     customers  outside  the  United  States</td>
    </tr>
    <tr>
      <td>Some  of these sales were to     <font color="blue">governmental</font> entities and other <font color="blue">organizations with extended payment terms</font></td>
    </tr>
    <tr>
      <td>A     number  of factors, including political or <font color="blue">economic instability</font> in the     countries where we do business, <font color="blue">could affect payment terms</font> and our ability     to <font color="blue">collect foreign receivables</font></td>
    </tr>
    <tr>
      <td>We have little <font color="blue">influence over</font> these factors     and  changes  could have a material adverse <font color="blue">impact on</font> our business</td>
    </tr>
    <tr>
      <td>In     addition, foreign sales are influenced by fluctuations in <font color="blue">currency exchange</font>     rates, mainly in the euro</td>
    </tr>
    <tr>
      <td>In <font color="blue">recent years</font>, our sales have <font color="blue">been positively</font>     <font color="blue">impacted by increases</font> in the value of the <font color="blue">euro relative</font> to the US dollar</td>
    </tr>
    <tr>
      <td><font color="blue">Decreases  </font>in  the value of the <font color="blue">euro relative</font> to the US <font color="blue">dollar would</font>     <font color="blue">negatively</font> impact our sales</td>
    </tr>
    <tr>
      <td>11       _________________________________________________________________    [51]Table of <font color="blue">Contents       </font>An <font color="blue">inability</font> to meet the <font color="blue">requirements</font> of Section 404 of the Sarbanes-Oxley     Act of 2002 could <font color="blue">adversely</font> affect investor confidence and, as a result, our     stock price</td>
    </tr>
    <tr>
      <td>During fiscal 2005 and 2004, we expended <font color="blue">significant</font> resources to comply     with the <font color="blue">requirements</font> of Section 404 of the Sarbanes-Oxley Act of 2002</td>
    </tr>
    <tr>
      <td>The     <font color="blue">requirements</font> of this Act must be maintained quarterly and are likely to     evolve as the result of a <font color="blue">reassessment</font> of the Act’s <font color="blue">initial implementation</font></td>
    </tr>
    <tr>
      <td>Failure to respond to changes in the <font color="blue">requirements</font> of the Act, our <font color="blue">inability</font>     to <font color="blue">comply regularly with</font> the Act’s <font color="blue">requirements</font>, and the costs of ongoing     <font color="blue">compliance could</font> have a material <font color="blue">adverse affect on investor confidence</font> and     our business</td>
    </tr>
    <tr>
      <td>Stock option expensing could impact investors’ confidence in our stock     price</td>
    </tr>
    <tr>
      <td>In  December 2004, the <font color="blue">Financial Accounting Standard </font><font color="blue">board issued</font> SFAS     Nodtta 123(R),  Share-Based  Payment,  pursuant  to which all stock-based     <font color="blue">compensation awards must</font> be measured and expensed in <font color="blue">consolidated financial</font>     <font color="blue">statements beginning</font> for us with our <font color="blue">first fiscal quarter</font> of 2006</td>
    </tr>
    <tr>
      <td>Though we     have been including <font color="blue">footnote disclosure</font> of the impact of the expense that     would be <font color="blue">recorded under</font> SFAS Nodtta 123 to our earnings and <font color="blue">earnings per</font> share     in our <font color="blue">regularly published</font> SEC filings, the impact of this change to our     stock price, and to those <font color="blue">throughout</font> the market, is <font color="blue">uncertain at</font> this time</td>
    </tr>
  </tbody>
</table>